公开(公告)号：EP3985025A1

公开(公告)日：2022-04-20

申请号：EP20821874.3

申请日：2020-05-22

申请人： Green Cross Corporation ,  Mogam Institute for Biomedical Research

发明人： PARK, Hye-Young ,  SONG, Eun Jung ,  LEE, Eun Hee ,  YUM, Hye In ,  NAM, Hye Mi ,  KIM, Mun Kyung ,  LEE, Jee Won ,  SHEEN, Joong Hyuk ,  HUR, Min Kyu ,  LIM, So Jung ,  LIM, Ok Jae ,  LIM, Yang Mi ,  WON, Jong Hwa

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/00

摘要： The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.

公开(公告)号：EP3699199A2

公开(公告)日：2020-08-26

申请号：EP18868854.3

申请日：2018-10-22

申请人： Green Cross Corporation ,  Mogam Institute for Biomedical Research

发明人： KIM, Ki Su ,  JEONG, Jun Hong ,  KIM, Dong Sik ,  LIM, Yang Mi ,  PARK, Yong Yea ,  LIM, Hyung Kwon ,  WON, Jong Wha

IPC分类号： C07K16/30

摘要： The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.